Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD. Li R, et al. Among authors: dickstein r. Nat Med. 2024 Aug;30(8):2372. doi: 10.1038/s41591-024-03137-w. Nat Med. 2024. PMID: 38890533 No abstract available.
Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.
Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Kamat AM, et al. Among authors: dickstein rj. J Urol. 2012 Mar;187(3):862-7. doi: 10.1016/j.juro.2011.10.144. Epub 2012 Jan 15. J Urol. 2012. PMID: 22245325 Free PMC article. Clinical Trial.
Clinical outcomes of cT1 micropapillary bladder cancer.
Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM. Willis DL, et al. J Urol. 2015 Apr;193(4):1129-34. doi: 10.1016/j.juro.2014.09.092. Epub 2014 Sep 22. J Urol. 2015. PMID: 25254936 Free PMC article.
Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.
Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-González G, Katz RL, Wu X, Barton Grossman H, Dinney CP. Kamat AM, et al. Among authors: dickstein rj. BJU Int. 2016 May;117(5):754-60. doi: 10.1111/bju.13186. Epub 2015 Jul 3. BJU Int. 2016. PMID: 26032953 Free PMC article.
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
Tyson MD, Morris D, Palou J, Rodriguez O, Mir MC, Dickstein RJ, Guerrero-Ramos F, Scarpato KR, Hafron JM, Messing EM, Cutie CJ, Maffeo JC, Raybold B, Chau A, Stromberg KA, Keegan KA. Tyson MD, et al. Among authors: dickstein rj. J Urol. 2023 May;209(5):890-900. doi: 10.1097/JU.0000000000003195. Epub 2023 Apr 7. J Urol. 2023. PMID: 37026631 Clinical Trial.
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Rose KM, Murray KS, Labbate C, Woldu S, Linehan J, Jacob J, Kaimakliotis H, Dickstein R, Feldman A, Matin SF, Lotan Y, Humphreys MR, Sexton WJ. Rose KM, et al. Among authors: dickstein r. Eur Urol Focus. 2023 Sep;9(5):807-812. doi: 10.1016/j.euf.2023.03.016. Epub 2023 Apr 12. Eur Urol Focus. 2023. PMID: 37059620 Review.
164 results